ExoLyra

ExoLyra is a preclinical-stage biotechnology company specializing in the development of engineered exosome-based therapeutics. Spun out of the University of California, Irvine, the company leverages a proprietary platform to design exosomes with enhanced targeting and payload delivery capabilities. Their primary focus is on addressing unmet needs in oncology and inflammatory diseases by utilizing the natural communication properties of exosomes to deliver therapeutic agents directly to diseased cells. ExoLyra's technology aims to overcome traditional drug delivery barriers, such as the blood-brain barrier and systemic toxicity.